Pathfinder Cell Therapy (Pathfinder Cell Therapy) EBIT : $-0.78 Mil (TTM As of Sep. 2015)

View and export this data going back to . Start your Free Trial

What is Pathfinder Cell Therapy EBIT?

Pathfinder Cell Therapy's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2015 was $-0.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2015 was $-0.78 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pathfinder Cell Therapy's annualized ROC % for the quarter that ended in Sep. 2015 was -15.62%. Pathfinder Cell Therapy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Pathfinder Cell Therapy EBIT Historical Data

The historical data trend for Pathfinder Cell Therapy's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pathfinder Cell Therapy EBIT Chart

Pathfinder Cell Therapy Annual Data

Trend

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

EBIT

Get a 7-Day Free Trial

-0.83

-3.62

-2.06

-1.60

-1.12

Pathfinder Cell Therapy Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15
EBIT	Get a 7-Day Free Trial															-0.21	-0.22	-0.20	-0.14	-0.21

Competitive Comparison of Pathfinder Cell Therapy's EBIT

For the Biotechnology subindustry, Pathfinder Cell Therapy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pathfinder Cell Therapy's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pathfinder Cell Therapy's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pathfinder Cell Therapy's EV-to-EBIT falls into.

Pathfinder Cell Therapy EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2015 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78 Mil.

Pathfinder Cell Therapy (OTCPK:PFND) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pathfinder Cell Therapy's annualized ROC % for the quarter that ended in Sep. 2015 is calculated as:

	ROC % (Q: Sep. 2015 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2015 )	+	Invested Capital (Q: Sep. 2015 ))	/ count )
=	-0.836 * ( 1 - 0% )	/	( (5.262	+	5.443)	/ 2 )
=	-0.836	/	5.3525
=	-15.62 %

where

	Invested Capital		(Q: Jun. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.049	-	1.259	-	( 0	-	max(0, 6.49	-	0.018	+	0	))
=	5.262

	Invested Capital		(Q: Sep. 2015 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.039	-	1.356	-	( 0.004	-	max(0, 6.769	-	0.009	+	0.004	))
=	5.443

Note: The Operating Income data used here is four times the quarterly (Sep. 2015) data.

2. Joel Greenblatt's definition of Return on Capital:

Pathfinder Cell Therapy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2015 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2015 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2015		Q: Sep. 2015
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.836	/	( ( (0 + max(-1.241, 0))	+	(0 + max(-1.351, 0)) )	/	2 )
=	-0.836	/	( ( 0	+	0 )	/	2 )
=	-0.836	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.018)	-	(1.259	+	0	+	0)
=	-1.241

	Working Capital		(Q: Sep. 2015 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.005)	-	(1.356	+	0	+	0)
=	-1.351

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2015) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pathfinder Cell Therapy's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2015 )
	=	-0.775	/	0.000
	=	%

Pathfinder Cell Therapy EBIT Related Terms

Thank you for viewing the detailed overview of Pathfinder Cell Therapy's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pathfinder Cell Therapy Inc (OTCPK:PFND) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

12 Bow Street, Cambridge, MA, USA, 02138

Website

http://www.pathfindercelltherapy.com

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells ("PCs") themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.

Executives

John J Alam	director	130 WAVERLY STREET, CAMBRIDGE MA 02139
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090

Pathfinder Cell Therapy (Pathfinder Cell Therapy) Headlines

No Headlines